Search research articles
Contact Us
Filters
Showing results (351-360 of 564) with videos related to
Page
of 57
Sort By:
Progress in Clinical and Biological Research
|
January 1, 1988
M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium
C N Sternberg, A Yagoda, H I Scher, et al.
European Urology
|
November 8, 2011
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Guru Sonpavde, Toni K Choueiri, Bernard Escudier, et al.
Clinical Genitourinary Cancer
|
October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
Cora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, George Wilding, Edwin Posadas, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Future Oncology (London, England)
|
October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Urology
|
May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, Christophe Massard, Mitchell E Gross, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
Page
of 57
Search research articles
Search
Showing results (351-360 of 564) with videos related to
Sort By:
Page
of 57
Progress in Clinical and Biological Research
|
January 1, 1988
M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium
C N Sternberg, A Yagoda, H I Scher, et al.
European Urology
|
November 8, 2011
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Guru Sonpavde, Toni K Choueiri, Bernard Escudier, et al.
Clinical Genitourinary Cancer
|
October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
Cora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, George Wilding, Edwin Posadas, et al.
ESMO Open
|
May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy
A Bamias, A S Merseburger, Y Loriot, et al.
Future Oncology (London, England)
|
October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region
Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Urology
|
May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer
Evan Y Yu, Christophe Massard, Mitchell E Gross, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2018
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
A J Armstrong, P Lin, C S Higano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
Page
of 57